[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hallym University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100641829","cgm-guided-patch-pump-vs-basal-bolus-injection-for-steroid-induced-hyperglycemia-in-sudden-sensorineural-hearing-loss-ship-trial-100641829",false,"NCT07652528","CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial","Steroid-induced Hyperglycemia Management With Insulin Patch Pump in Sudden Sensorineural Hearing Loss: a CGM-guided Exploratory Randomized Controlled Trial (SHIP Trial)","SHIP","Inclusion Criteria:\n\n1. Age ≥19 years\n2. Idiopathic SSNHL: ≥30 dB sensorineural hearing loss across ≥3 consecutive frequencies within 72 hours\n3. Affected ear PTA4 (mean of 0.5\u002F1\u002F2\u002F4 kHz) ≥40 dB HL (moderate or greater)\n4. Planned methylprednisolone 48 mg\u002Fday orally once in the morning\n5. At least one of: known T2DM; HbA1c 5.7-10.0% within 3 months; POC glucose ≥140 mg\u002FdL ×2 (≥2h apart, ≥1 postprandial) within 24h of steroid\n6. If on prior insulin: outpatient TDD ≤30 U\u002Fday\n7. Able to eat ≥2 meals\u002Fday, wear CGM and patch pump, use smartphone\n8. Willing to undergo 2-night inpatient admission (Day 1-3)\n9. Written informed consent\n\nExclusion Criteria:\n\n1. Type 1 DM, LADA, pancreatogenic DM, DKA\u002FHHS within 12 months, ketonuria at enrollment\n2. Enrollment POC ≥350 mg\u002FdL or immediate IV insulin requirement\n3. HbA1c ≥10.0%\n4. eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or dialysis\n5. Pregnancy\u002Fbreastfeeding; women of childbearing potential: positive urine hCG\n6. ICU, sepsis, NPO, TPN\u002Fenteral nutrition\n7. Severe hepatic failure (Child-Pugh C)\n8. Dexamethasone, divided-dose, or pulse steroids planned\n9. Prior CSII or AID device user\n10. Skin adhesive allergy precluding CGM or patch pump use\n11. Insufficient cognitive function for device or dosing table use\n12. Planned MRI requiring repeated CGM\u002Fpump removal\n13. PTA \\>70 dB (profound hearing loss requiring combined intratympanic steroid)","ALL","19 Years",{"count":20,"type":21},44,"ESTIMATED","INTERVENTIONAL",[24],"NA","This exploratory randomized controlled trial evaluates whether a CGM-guided temporary patch pump (CareLevo CSII) reduces glucocorticoid-induced hyperglycemia (GIH) compared to a Lantus-based basal-bolus injection (MDI) regimen in patients with sudden sensorineural hearing loss (SSNHL) and type 2 diabetes or prediabetes receiving high-dose systemic corticosteroids (methylprednisolone 48 mg\u002Fday).\n\nPatients with SSNHL are treated with high-dose oral corticosteroids as standard of care, which often causes significant postprandial hyperglycemia - particularly in patients with pre-existing diabetes or prediabetes. No randomized trial has investigated the optimal insulin delivery strategy for this specific clinical scenario.\n\nAll enrolled participants undergo a 2-night inpatient admission (Day 1-3) for safe insulin initiation and device education, followed by outpatient management (Day 4-14). All participants wear a CareSens Air continuous glucose monitor (CGM, 15-day sensor) throughout Day 1-14.\n\nParticipants meeting insulin activation criteria are randomized 1:1 to:\n\n* Arm A (CSII): CareLevo patch pump using a steroid-wave basal profile and carbohydrate-band meal bolus via the app's bolus calculator (CGM-integrated, IOB-adjusted)\n* Arm B (MDI): Insulin glargine U-100 (Lantus) qAM plus Fiasp prandial bolus via pen using a pre-printed dose table with identical carbohydrate-band algorithm\n\nBoth arms use identical glycemic targets, carbohydrate-band bolus algorithm (ICR\u002FISF identical), and correction rules. The primary difference is insulin delivery (patch pump vs. pen injection) and basal profile (steroid-wave CSII vs. flat glargine). The primary outcome is 24-hour CGM Time Above Range (TAR) \\>180 mg\u002FdL averaged over the 9-day high-dose steroid period (Day 1-9).",[27,28],"Sudden Sensorineural Hearing Loss (SSNHL)","Prediabetes \u002F Type 2 Diabetes",[30,31,32,33,34,35],"Sudden Sensorineural Hearing Loss","Glucocorticoid-Induced Hyperglycemia","Steroid-Induced Hyperglycemia","Continuous Glucose Monitoring","Insulin Pump Therapy","Patch Pump","NOT_YET_RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-17","ACTUAL",{"date":42,"type":21},"2026-08",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Hallym University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":5},"100638613","brown-adipose-tissue-as-a-mechanistic-determinant-of-semaglutide-treatment-response-in-obesity-bat-sema-study-100638613","NCT07621640","Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)","Brown Adipose Tissue as a Mechanistic Determinant of GLP-1 Receptor Agonist Treatment Response in Adults With Obesity: A Multicenter Prospective Cohort Study Using ¹⁸FDG-PET\u002FCT and Cold Stimulation Protocol","BAT-Sema","Inclusion Criteria:\n\n1. Age 20-70 years at the time of enrollment\n2. Initiating semaglutide (Wegovy) treatment for obesity (newly starting treatment)\n3. BMI ≥ 27 kg\u002Fm² with at least one weight-related comorbidity:\n\n   * Hypertension (SBP ≥130 or DBP ≥80 mmHg, or on antihypertensive medication)\n   * Dyslipidemia (LDL-C ≥130, TG ≥150, or low HDL-C, or on lipid-lowering medication)\n   * Non-alcoholic fatty liver disease (NAFLD\u002FMASLD, confirmed by imaging or ALT\u002FAST ≥1.5× ULN)\n   * Obstructive sleep apnea (AHI ≥5\u002Fhr or clinically diagnosed)\n   * Established cardiovascular disease (CAD, stroke, PAD)\n   * Obesity-related osteoarthritis of knee or hip with functional impairment OR BMI ≥ 30 kg\u002Fm² (regardless of comorbidity)\n4. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 or type 2 diabetes mellitus\n2. History of neck surgery or radiation therapy to the neck\n3. Use of anti-obesity medications within 1 month prior to enrollment, or current use of beta-adrenergic blocking agents\n4. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n5. Active malignancy, severe renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), severe hepatic disease, or other severe endocrine disorders\n6. Pregnancy or breastfeeding\n7. Severe psychiatric illness or cognitive impairment precluding informed consent\n8. Contraindication to MRI (pacemaker, cochlear implant, non-MRI-compatible implants)\n9. Severe claustrophobia","20 Years","70 Years",{"count":59,"type":21},80,[24],"This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly injectable weight loss medication. Participants who are starting semaglutide treatment will undergo ¹⁸FDG-PET\u002FCT imaging before and after 24 weeks of treatment. Prior to each PET\u002FCT scan, participants will wear a water-circulating cooling vest to activate BAT. By measuring BAT activity at baseline and comparing it with the degree of weight loss and metabolic improvement at 24 weeks, the investigators aim to identify BAT as a predictive biomarker for personalized obesity treatment.",[63,64,65],"Obesity","Metabolic Syndrome","Brown Adipose Tissue",[67,68,69,63,70,71,72,73,74],"Brown adipose tissue","Semaglutide","GLP-1 receptor agonist","FDG-PET\u002FCT","BAT","Biomarker","Weight loss","PDFF","2026-05-27",{"date":77,"type":40},"2026-06-02",{"date":79,"type":21},"2026-06",{"date":81,"type":21},"2031-02",{"name":46,"class":47},""]